X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs CIPLA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH CIPLA PANACEA BIOTECH/
CIPLA
 
P/E (TTM) x 169.7 45.1 376.4% View Chart
P/BV x 3.8 3.9 97.5% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PANACEA BIOTECH   CIPLA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
CIPLA
Mar-17
PANACEA BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs149622 23.9%   
Low Rs82458 18.0%   
Sales per share (Unadj.) Rs84.1181.9 46.3%  
Earnings per share (Unadj.) Rs-18.312.9 -142.2%  
Cash flow per share (Unadj.) Rs-6.729.3 -22.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs83.7155.7 53.8%  
Shares outstanding (eoy) m61.25804.51 7.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.43.0 46.2%   
Avg P/E ratio x-6.342.0 -15.0%  
P/CF ratio (eoy) x-17.218.4 -93.6%  
Price / Book Value ratio x1.43.5 39.8%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m7,074434,516 1.6%   
No. of employees `0002.823.0 11.9%   
Total wages/salary Rs m1,44926,338 5.5%   
Avg. sales/employee Rs Th1,874.16,349.1 29.5%   
Avg. wages/employee Rs Th527.01,143.0 46.1%   
Avg. net profit/employee Rs Th-407.7449.3 -90.7%   
INCOME DATA
Net Sales Rs m5,154146,302 3.5%  
Other income Rs m1002,287 4.4%   
Total revenues Rs m5,254148,589 3.5%   
Gross profit Rs m-76624,758 -3.1%  
Depreciation Rs m71113,229 5.4%   
Interest Rs m1,5031,594 94.3%   
Profit before tax Rs m-2,88112,222 -23.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-6-70 8.2%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m171,798 0.9%   
Profit after tax Rs m-1,12110,354 -10.8%  
Gross profit margin %-14.916.9 -87.9%  
Effective tax rate %-0.614.7 -4.0%   
Net profit margin %-21.87.1 -307.4%  
BALANCE SHEET DATA
Current assets Rs m3,81087,370 4.4%   
Current liabilities Rs m8,36533,081 25.3%   
Net working cap to sales %-88.437.1 -238.2%  
Current ratio x0.52.6 17.2%  
Inventory Days Days15687 179.0%  
Debtors Days Days6762 107.9%  
Net fixed assets Rs m14,480111,567 13.0%   
Share capital Rs m611,609 3.8%   
"Free" reserves Rs m903123,645 0.7%   
Net worth Rs m5,127125,254 4.1%   
Long term debt Rs m5,83236,454 16.0%   
Total assets Rs m19,433209,532 9.3%  
Interest coverage x-0.98.7 -10.6%   
Debt to equity ratio x1.10.3 390.8%  
Sales to assets ratio x0.30.7 38.0%   
Return on assets %2.05.7 34.4%  
Return on equity %-21.98.3 -264.6%  
Return on capital %3.68.5 42.8%  
Exports to sales %24.534.2 71.7%   
Imports to sales %10.28.3 122.1%   
Exports (fob) Rs m1,26450,050 2.5%   
Imports (cif) Rs m52512,203 4.3%   
Fx inflow Rs m1,53951,066 3.0%   
Fx outflow Rs m94217,678 5.3%   
Net fx Rs m59733,388 1.8%   
CASH FLOW
From Operations Rs m59923,824 2.5%  
From Investments Rs m-438-13,127 3.3%  
From Financial Activity Rs m-303-13,239 2.3%  
Net Cashflow Rs m-141-2,478 5.7%  

Share Holding

Indian Promoters % 74.5 16.0 465.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.6 12.2 4.9%  
FIIs % 1.3 23.7 5.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.6 26.2 90.1%  
Shareholders   10,259 161,166 6.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 20, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS